Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial
Robert J. Motzer(Memorial Sloan Kettering Cancer Center), Paul B. Robbins(Pfizer (United States)), Thomas Powles(St Bartholomew's Hospital), Laurence Albigès(Institut Gustave Roussy), John B.A.G. Haanen(The Netherlands Cancer Institute), James Larkin(Royal Marsden NHS Foundation Trust), Xinmeng Jasmine Mu(Pfizer (United States)), Keith A. Ching(Pfizer (United States)), Motohide Uemura(Osaka University Hospital), Sumanta K. Pal(City of Hope), B. Yа. Alekseev, Gwénaëlle Gravis(Institut Paoli-Calmettes), Matthew T. Campbell(The University of Texas MD Anderson Cancer Center), Konstantin Penkov, Jae‐Lyun Lee(Ulsan College), Subramanian Hariharan(Pfizer (United States)), Xiao Wang(Pfizer (United States)), Weidong Zhang(Pfizer (United States)), Jing Wang(Pfizer (United States)), Aleksander Chudnovsky(Pfizer (United States)), Alessandra di Pietro(Pfizer (Italy)), Amber C. Donahue(Pfizer (United States)), Toni K. Choueiri(Brigham and Women's Hospital)
Cited by 515Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis